Patient characteristics, including risk factors and treatments
| RAS inhibitor | No RAS inhibitor | |
| Number of patients | 19 | 60 |
| Mean (SD) age (years) | 61 (9) | 62 (8) |
| Men, n (%) | 13 (68) | 45 (75) |
| Women, n (%) | 6 (33) | 15 (25) |
| Risk factors, n (%) | ||
| Smoking | 3 (16) | 10 (17) |
| Hypertension | 9 (47) | 21 (35) |
| Diabetes mellitus | 2 (10) | 4 (7) |
| Hypercholesterolaemia | 14 (73) | 41 (68) |
| Mean (SD) plasma cholesterol, mmol/l | 5.9 (1.2) | 5.2 (0.9) |
| Medication, n (%) | ||
| Aspirin | 14 (74) | 48 (80) |
| β Blockers | 13 (68) | 33 (55) |
| Calcium channel blockers | 11 (58) | 34 (57) |
| HMG-CoA reductase inhibitors | 7 (37) | 31 (52) |
| Nitroglycerin | 12 (63) | 34 (57) |
RAS, renin angiotensin system; HMG-CoA, hydroxymethyl-glutaryl-CoA.